Real‐Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2V617F mutation in Philadelphia‐negative chronic myeloproliferative neoplasms

Philadelphia‐negative chronic myeloproliferative neoplasms (MPNs) are clonal disorders that present JAK2V617F mutation in 50–95% of cases. The main objective of this study was the comparison of two PCR methods, real‐time (qPCR) and droplet digital PCR (DD‐PCR) for detection of the JAK2V617F mutation, to assess analytic sensitivity, specificity, and feasibility of the two methods.

[1]  M. Konopleva,et al.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Hasselbalch,et al.  The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders , 2007, British journal of haematology.

[3]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[4]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[5]  M. Cazzola,et al.  A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications , 2010, Leukemia.

[6]  S. Langabeer,et al.  Monitoring Residual Disease in the Ph-Negative Myeloproliferative Neoplasms Post-Allogeneic Stem Cell Transplantation: More Mutations and More Methodologies , 2014, Front. Oncol..

[7]  Alexandra S. Whale,et al.  Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation , 2012, Nucleic acids research.

[8]  P. Guglielmelli,et al.  JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment , 2011, Therapeutic advances in hematology.

[9]  W. Dameshek.  Editorial: Some Speculations on the Myeloproliferative Syndromes , 1951 .

[10]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[11]  Min Yu,et al.  Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. , 2014, The Journal of molecular diagnostics : JMD.

[12]  T. Barbui,et al.  Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.

[13]  T. Barbui,et al.  Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden , 2007, Leukemia.

[14]  Jim F Huggett,et al.  Evaluation of digital PCR for absolute DNA quantification. , 2011, Analytical chemistry.

[15]  S. Langabeer,et al.  Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms , 2013, Clinical chemistry and laboratory medicine.

[16]  S. Chevret,et al.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.

[17]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[18]  H. Kantarjian,et al.  PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders , 2007 .

[19]  Y. Hildebrandt,et al.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. , 2010, Blood.

[20]  J. Huggett,et al.  Digital PCR as a novel technology and its potential implications for molecular diagnostics. , 2013, Clinical chemistry.

[21]  J. Rowe,et al.  Allogeneic stem-cell transplantation for myelofibrosis , 2017, Current opinion in hematology.

[22]  D. Niederwieser,et al.  JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse , 2013, Haematologica.

[23]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[24]  M. McMullin,et al.  JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders , 2006, The Ulster medical journal.

[25]  S H Neoh,et al.  Quantitation of targets for PCR by use of limiting dilution. , 1992, BioTechniques.

[26]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[27]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[28]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[29]  F. Passamonti,et al.  Clinical relevance of JAK2 (V617F) mutant allele burden , 2009, Haematologica.

[30]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[31]  G. Massonnet,et al.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.

[32]  Benjamin J. Hindson,et al.  Evaluation of a Droplet Digital Polymerase Chain Reaction Format for DNA Copy Number Quantification , 2011, Analytical chemistry.

[33]  H. Kantarjian,et al.  PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. , 2007, Cancer.

[34]  A. Nagler,et al.  JAK2V617F allele burden is associated with transformation to myelofibrosis , 2012, Leukemia & lymphoma.

[35]  A. Jones,et al.  Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. , 2007, The Journal of molecular diagnostics : JMD.

[36]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[37]  M. Møller,et al.  Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera , 2008, Annals of Hematology.

[38]  J. Kiladjian.  The spectrum of JAK2-positive myeloproliferative neoplasms. , 2012, Hematology. American Society of Hematology. Education Program.

[39]  T. Barbui,et al.  Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study , 2013, Leukemia.